Pharis Mohideen - Net Worth and Insider Trading

Pharis Mohideen Net Worth

The estimated net worth of Pharis Mohideen is at least $340,552 dollars as of 2024-11-29. Pharis Mohideen is the Chief Medical Officer of DBV Technologies SA and owns about 111,110 shares of DBV Technologies SA (DBVT) stock worth over $340,552. Details can be seen in Pharis Mohideen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pharis Mohideen has not made any transactions after 2024-11-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Pharis Mohideen

Pharis Mohideen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Pharis Mohideen owns 3 companies in total, including Millendo Therapeutics Inc (MLND) , Tempest Therapeutics Inc (TPST) , and DBV Technologies SA (DBVT) .

Click here to see the complete history of Pharis Mohideen’s form 4 insider trades.

Insider Ownership Summary of Pharis Mohideen

Ticker	Comapny	Transaction Date	Type of Owner
MLND	Millendo Therapeutics Inc	2019-01-15	Chief Medical Officer
TPST	Tempest Therapeutics Inc	2018-12-07	Chief Medical Officer
DBVT	DBV Technologies SA	2024-11-21	Chief Medical Officer

Pharis Mohideen Latest Holdings Summary

Pharis Mohideen currently owns a total of 1 stock. Pharis Mohideen owns 111,110 shares of DBV Technologies SA (DBVT) as of November 25, 2024, with a value of $340,552.

Latest Holdings of Pharis Mohideen

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DBVT	DBV Technologies SA	2024-11-25	111,110	3.07	340,552

Holding Weightings of Pharis Mohideen

Pharis Mohideen Form 4 Trading Tracker

According to the SEC Form 4 filings, Pharis Mohideen has made a total of 6 transactions in DBV Technologies SA (DBVT) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in DBV Technologies SA is the sale of 907 shares on November 25, 2024, which brought Pharis Mohideen around $499.

Insider Trading History of Pharis Mohideen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Pharis Mohideen Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Pharis Mohideen Ownership Network

Ownership Network List of Pharis Mohideen

No Data

Ownership Network Relation of Pharis Mohideen

Pharis Mohideen Owned Company Details

What does Millendo Therapeutics Inc do?

Who are the key executives at Millendo Therapeutics Inc?

Pharis Mohideen is the Chief Medical Officer of Millendo Therapeutics Inc. Other key executives at Millendo Therapeutics Inc include Chief Medical Officer Christophe Arbet-engels , Chief Development Officer Ryan Zeidan , and director & President and CEO Julia C. Owens .

Millendo Therapeutics Inc (MLND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Millendo Therapeutics Inc (MLND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Millendo Therapeutics Inc (MLND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Millendo Therapeutics Inc (MLND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Millendo Therapeutics Inc Insider Transactions

No Available Data

What does Tempest Therapeutics Inc do?

Who are the key executives at Tempest Therapeutics Inc?

Pharis Mohideen is the Chief Medical Officer of Tempest Therapeutics Inc. Other key executives at Tempest Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , director & Chief Executive Officer Stephen R Brady , and Chief Medical Officer Samuel Whiting .

Tempest Therapeutics Inc (TPST) Insider Trades Summary

Over the past 18 months, Pharis Mohideen made no insider transaction in Tempest Therapeutics Inc (TPST). Other recent insider transactions involving Tempest Therapeutics Inc (TPST) include a net sale of 787,999 shares made by Versant Venture Capital Vi, L.p. , a net purchase of 35,000 shares made by Stephen R Brady , and a net purchase of 4,672 shares made by Samuel Whiting .

In summary, during the past 3 months, insiders sold 0 shares of Tempest Therapeutics Inc (TPST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 787,999 shares of Tempest Therapeutics Inc (TPST) were sold and 39,672 shares were bought by its insiders, resulting in a net sale of 748,327 shares.

Tempest Therapeutics Inc (TPST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tempest Therapeutics Inc Insider Transactions

No Available Data

What does DBV Technologies SA do?

Who are the key executives at DBV Technologies SA?

Pharis Mohideen is the Chief Medical Officer of DBV Technologies SA. Other key executives at DBV Technologies SA include director & Chief Executive Officer Daniel Tasse , Chief Financial Officer Virginie Boucinha , and director & 10 percent owner Julian Baker .

DBV Technologies SA (DBVT) Insider Trades Summary

Over the past 18 months, Pharis Mohideen made 5 insider transaction in DBV Technologies SA (DBVT) with a net sale of 8,329. Other recent insider transactions involving DBV Technologies SA (DBVT) include a net purchase of 17,094 shares made by Daniel Tasse , a net purchase of 15,000 shares made by Daniel B Soland , and a net purchase of 12,000 shares made by Timothy E Morris .

In summary, during the past 3 months, insiders sold 3,257 shares of DBV Technologies SA (DBVT) in total and bought 0 shares, with a net sale of 3,257 shares. During the past 18 months, 6,686 shares of DBV Technologies SA (DBVT) were sold and 22,960 shares were bought by its insiders, resulting in a net purchase of 16,274 shares.

DBV Technologies SA (DBVT)'s detailed insider trading history can be found in Insider Trading Tracker table.

DBV Technologies SA Insider Transactions

No Available Data

Pharis Mohideen Mailing Address

Above is the net worth, insider trading, and ownership report for Pharis Mohideen. You might contact Pharis Mohideen via mailing address: C/o Ovascience, Inc., 9 Fourth Avenue, Waltham Ma 02451.

Discussions on Pharis Mohideen

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.